Drug intelligence / Profile preview

AD-115A

Development stage: Unknown
Modality: Small Molecules
Administration: Oral

Overview

AD-115A is an investigational drug currently being evaluated in clinical trials. It is a small molecule administered orally, and its safety and pharmacokinetic properties are being compared to another investigational compound, AD-1151, in healthy adults. The precise mechanism of action for AD-115A has not been disclosed or remains unknown at this stage. There is no information available regarding its primary indication or therapeutic target[1][2].

Other names: revaprazan sulfate

Targets

ATP4A (Potassium–transporting ATPase alpha chain 1)

Beyond the preview

Go deeper on AD-115A.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AD-115A.

Explore the full profile